Last reviewed · How we verify
Amlodipine + Indapamide
Amlodipine relaxes blood vessels by blocking calcium channels, while indapamide reduces blood volume and sodium levels through diuretic action, together lowering blood pressure.
Amlodipine relaxes blood vessels by blocking calcium channels, while indapamide reduces blood volume and sodium levels through diuretic action, together lowering blood pressure. Used for Hypertension, Essential hypertension in patients requiring combination therapy.
At a glance
| Generic name | Amlodipine + Indapamide |
|---|---|
| Sponsor | Centre for Chronic Disease Control, India |
| Drug class | Calcium channel blocker + Thiazide-like diuretic combination |
| Target | L-type voltage-gated calcium channels (amlodipine); sodium-chloride cotransporter (indapamide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing blood volume and intracellular calcium in vascular smooth muscle. The combination provides synergistic antihypertensive effects through complementary mechanisms.
Approved indications
- Hypertension
- Essential hypertension in patients requiring combination therapy
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Fatigue
- Hypokalemia
- Hyperuricemia
- Flushing
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Antihypertensive Drug Selection Based on Hemodynamic Phenotypes (PHASE4)
- Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension (PHASE3)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (PHASE3)
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine + Indapamide CI brief — competitive landscape report
- Amlodipine + Indapamide updates RSS · CI watch RSS
- Centre for Chronic Disease Control, India portfolio CI